RU2256458C1 - Preparation for preventing and treating gynecological diseases in cows and sows - Google Patents

Abstract

FIELD: veterinary science.

SUBSTANCE: the suggested preparation includes an active substance as a lipophilic fraction of porcine placenta and a solvent as sterile vegetable oil at the following ratio of components, weight%: lipophilic fraction of porcine placental tissues 0.5 - 1; vegetable oil. The preparation provides decreased sickness rate with postnatal gynecological diseases in cows and sows along with increased conception rate during the first insemination.

EFFECT: higher efficiency of prophylaxis and therapy.

3 tbl

Description

The invention relates to the field of veterinary medicine and can be used for the prevention and treatment of gynecological diseases in cows and sows.

Known anti-inflammatory drug for the prevention and treatment of postpartum complications in cows and other farm animals based on placental tissues. The anti-inflammatory drug is prepared from human placental tissue - the umbilical cord, with the addition of sterile distilled water in the ratio (1: 0.8) - (1: 1.2). / Patent RU 2035910, IPC 6 A 61 K 35/50, publication date of the formula 1995.05.27 /

A known preparation is obtained by separating the liquid component from the placenta by heating in a microwave oven in a special vessel with a perforated bottom, while the liquid component is separated by gravity, and heating is not higher than 60 ° C, and 0.9% is used as the dilution medium for the liquid phase sodium chloride solution. / Patent RU 2138273, IPC 6 A 61 K 35/50, publication date of the formula 1999.09.27 /

The disadvantages of the drugs is that they did not use a specially isolated lipophilic fraction of pork placenta. In addition, the disadvantage of the first drug is the use of an expensive human placenta, which requires a preliminary check for AIDS, hepatitis and other diseases.

The closest analogue is the drug - emulsified denatured placenta, which is made from human placenta. The preparation is a sterile emulsion of a white or white with a yellowish tint color, specific smell / I.F. Klenova, N.A. Yaremenko - M .: Selkhozizdat, 2000, - p. 466 /.

Its disadvantages are the use of feedstock - human placenta, resulting in low satisfaction of the needs of veterinary medicine, as well as species incompatibility of protein and polysaccharide components of the drug. The disadvantages of PDE preparations are the low effectiveness of the action, the reason for which is the use of outdated technologies for its production. The methods for obtaining this drug are based on processes:

- denaturation of placental tissues with oxidizing agents

- hydrogen peroxide

These processes are aimed at the destruction of valuable biologically active substances contained in placental tissue.

The technical result of the invention is improving efficiency, expanding the raw material base for obtaining highly active biogenic stimulants in veterinary practice and eliminating species incompatibility.

This goal is achieved by the use of a drug consisting of a lipophilic fraction of the placenta of pork and vegetable oil in the following ratio of components wt.%:

Lipophilic fraction of pork placenta - 0.5-1

Vegetable oil - the rest.

The drug is made as follows.

The pork placenta is washed with running water, fragmented and subjected to rapid freezing in pairs of liquid nitrogen to a temperature of -80 ° C - -120 ° C at a speed of 30 degrees per minute.

Cryopreservation of pork placenta is carried out in a cryomill when cooled with liquid nitrogen vapor to temperatures of -80 ° C - -120 ° C. The degree of tissue grinding is 20-30 microns. The resulting powder from placental tissues is subjected to lyophilization at temperatures in the range of -10 ° C to -20 ° C and a residual pressure in the chamber of not higher than 0.1 mm RT. Art. within 16-20 hours. The result is a powder with a moisture content of 3-5%.

Extraction of lyophilized powder of porcine placenta is carried out on a low-temperature extraction unit using freon, which is absolutely inert to the extracted fraction. Liquid freon is supplied from pressure vessels at a pressure of 6-8 atm and a temperature of 30-35 ° C to the extractor, where the previously dried powder is located. The solvent passes through a layer of freeze-dried powder of porcine placenta and extracts fat-soluble substances from it, then it is poured through a fine filter into an evaporator. In the evaporator, by reducing the pressure to atmospheric, given the low boiling point of the freons (-20 - -40 ° C) and their volatility, it is possible to completely remove the solvent (it is sent for regeneration and reuse). As a result of this stage, it is possible to obtain a pure lipophilic complex, while maintaining the stability of the extracted substances and their native complex. The output of the lipophilic fraction is 2-3% of the loaded lyophilized powder. The lipophilic fraction is a brown-brown mass, softening at room temperature. Store it in a freezer at a temperature of -18 ° C.

Then the obtained fraction is mechanically mixed with sterile vegetable oil in a ratio of components wt.%:

Lipophilic fraction of porcine placental tissue - 0.05-1

Vegetable oil - the rest.

Optimum is the following ratio of components, wt.%:

Lipophilic fraction of porcine placental tissue - 0.075

Vegetable oil - the rest.

A decrease in the content of pork placenta lipophilic fraction in the preparation reduces the effect of the application, and an increase does not lead to an increase in the therapeutic effect.

The preparation contains a complex of biologically active substances: amino acids, peptides, hexuronic acids, polysaccharides, vitamins, microelements. The drug has an immunostimulating effect, normalizes indicators of cellular and humoral immunity, has an anti-inflammatory effect, stimulates the enzyme system and normalizes the microbial composition of the digestive tract, has an adaptogenic and stress-protective effect, and increases the nonspecific resistance of the body.

The drug is used as follows.

Pre-heated to a temperature of + 36-37 ° C, the drug is administered intramuscularly at a dose of 0.001 ml / kg body weight according to the following scheme:

Table 1
Scheme of application of the claimed drug. Animal species Indications for use Application chart Cows prevention of subinvolution of the uterus immediately after birth, twice every 48 hours mastitis prevention 5-7 times with an interval of 48 hours shortening the service period 5-7 days after calving 5 times with an interval of 48 hours retention of the afterbirth immediately after birth, twice every 24 hours endometritis 5-7 times with an interval of 48 hours Pigs prevention of endometritis, metritis-mastitis-agalactia after farrowing twice with an interval of 48 hours treatment of endometritis, metritis-mastitis-agalactia 4-5 times with an interval of 48 hours

As a result of the tests of the drug, a high therapeutic and prophylactic effect was obtained, which is not inferior to the analogue drug, and in some cases exceeds it. Experiments to study the effectiveness of the drug for the prevention of postpartum diseases in cows from March 20 to July 30, 2003 were carried out in OSAO AK Slobozhansky of the Chuguevsky district of the Kharkov region on three groups of animals formed on the basis of paired analogues. Animals were in the same conditions of keeping and feeding. The diet is balanced in terms of basic nutritional components, animals used an active exercise. The cows of the first group (175 animals) were administered the claimed preparation intramuscularly immediately after delivery (separation of the placenta, abortion, or assisting with complications and pathological births) at a dose of 0.001 ml / kg of body weight twice with an interval of 48 hours. Before administration, the drug was preheated to a temperature of 36-37 ° C. Animals of the second group (156 animals) were administered subcutaneously with PDE in a dose of 20 ml twice with an interval of 48 hours. The cows of the third group (138 animals) were not used (control).

During the experiment, animals underwent daily clinical observation, taking into account the time of the disease, the manifestation of the first hunt, and the timing of fruitful insemination. The results of the experiment are presented in table 2. As can be seen from table 2, the best preventive effect was achieved when using the inventive drug. The data indicate that the claimed drug is an effective prophylactic for postpartum obstetric diseases and prevents diseases of cows with postpartum endometritis.

table 2
The effectiveness of the proposed drug in the prevention of postpartum obstetric diseases in cows Indicators Groups of animals The inventive drug PDE Without the use of the drug Number of animals, goal 175 156 138 Subinvolution of the uterus, goal
% 8
4,57 eleven
7.05 25
18.11 Ill with postpartum endometritis, goal
% nineteen
10.86 24
15.38 31
22.46 The period from calving to fertilization, days 46.2 ± 4.7 57.1 ± 6.0 63.0 ± 7.4 Fertilized at 1
insemination goal
% 152
86.86 131
83.97 103
74.64 Fertilization index 1.51 ± 0.18 1.84 ± 0.25 3.04 ± 1.08

The second experience in studying the effectiveness of the claimed drug for the prevention and treatment of postpartum diseases in cows was carried out from May 10 to July 30, 2003. Production tests of the effectiveness for the prevention of birth and postpartum diseases in cows were performed on 864 cows, divided into experimental (404 heads) and control (460 heads). The experimental cows for prophylactic purposes immediately after birth, intramuscularly twice with an interval of 48 hours was used the claimed drug in a dose of 0.001 ml / kg body weight. When delaying the placenta, the inventive preparation was used twice with an interval of 24 hours. Animals of the control group did not use drugs.

The incidence rates of cows for postpartum diseases are presented in table 3.

Table 3
The incidence of cows postpartum diseases Groups
animals Cow sick with birth and postpartum diseases Total Including retention of the afterbirth subinvolution
uterus endometritis Goal. % Goal. % Goal. % Goal % The first 404 heads 48 11.9 17 4.2 fifteen 3,7 16 4.0 Second 460 goals 69 16 26 5.7 22 4.8 21 4.6

Tests have shown the high efficiency of the claimed drug for the prevention and treatment of postpartum diseases in cows.

The applicant asks to name the claimed drug “Lipoton”.

Claims (1)

A drug for the prevention and treatment of gynecological diseases in cows and sows, including an active substance and a diluent, characterized in that the lipophilic fraction of pork placenta is used as the active substance, and sterile vegetable oil is used as the diluent, in the following ratio, wt. %: Lipophilic fraction of porcine placental tissue 0.5-1 Vegetable Oil Else